Editorial Videos

Doctor Harshit Jain, Founder and Global CEO of Doceree, spoke with Pharmaceutical Executive about leveraging point-of-care marketing momentum and its influence on decision making and how does Doceree maintain contextual relevance in marketing on a national scale.

Noah Nasser discusses one of the most critical components of working with RWD.

Michael Grosberg discusses the issues that need to be addressed to bring drug prices down for patients.

Derrick Gastineau discusses the importance of finding the right spaces to ensure patients see accurate information about medications.

Doctor Harshit Jain, Founder and Global CEO of Doceree, spoke with Pharmaceutical Executive about the role of AI in programmatic marketing, and the expectations of developments in communication between healthcare professionals and pharmaceutical brands.

Derrick Gastineau discusses the importance of patients’ hearing stories from other patients.

Noah Nasser discusses the importance of keeping data still.

With insured patients less likely to benefit, who actually does benefit from D2C?

Derrick Gastineau discusses how the focus on weight loss medications has shifted in recent years.

Michael Grosberg discusses how people with insurance will be impacted by D2C drug sales.

Rob Abbott, CEO, ISPOR, highlights how uniting regulators, payers, and academic leaders worldwide can accelerate access to innovative treatments and strengthen evidence-based healthcare.

Ron Lanton, partner, Lanton Law, warns that ongoing lawsuits targeting vaccine policy could create ripple effects across FDA decision-making and reshape how future emergency use authorizations are granted.

Ron Lanton, partner, Lanton Law, warns that recent changes to federal vaccine recommendations could trigger extensive litigation as insurers, providers, and patients face new access and coverage challenges.

Rob Abbott, CEO, ISPOR, highlights how AI is streamlining research and improving patient care while stressing the importance of human oversight.

Rob Abbott, CEO, ISPOR, highlights that the United States excels in areas like cancer screening and advanced medical technology while facing challenges such as rising costs, lack of universal coverage, and health outcomes that lag behind other high-income nations.

Rob Abbott, CEO, ISPOR, highlights how emerging data strategies, advanced technology, and a renewed focus on patient needs are setting the direction for the next era of healthcare worldwide.

Rob Abbott, CEO, ISPOR, explains how health economics and outcomes research is helping healthcare systems measure the true value of treatments, improve patient outcomes, and address rising drug costs globally.

Gene Mack, CEO, Gain Therapeutics, explains how the company’s Magellan AI platform analyzes novel protein binding sites to identify and design drug candidates beyond what’s currently available in the public domain.

Gene Mack, CEO, GAIN Therapeutics, highlights early Phase Ib data showing GT-02287 may enhance neuroprotection across a wider spectrum of Parkinson’s patients regardless of genetic status.

Gene Mack, CEO, GAIN Therapeutics, outlines how early trial results for GT-02287 are shaping the company’s strategy for advancing a potential new treatment for Parkinson’s disease.

Gene Mack, CEO, GAIN Therapeutics, shares how growing clinician confidence and strong early experiences helped accelerate enrollment in the company’s Phase Ib Parkinson’s disease trial.

Gen Li discusses when the industry can expect to start seeing technological advancements implemented.

Gen Li discusses the current state of technological advancement in clinical trials.

New technology has the potential to improve trial design and patient recruitment.

Dr. Zeskind discusses how Immuneering’s treatments can impact a broad range of cancer types.

Gen Li discusses how competition and other factors can impact existing issues with clinical trial design.

The side effects that come with many cancer treatments can cause people to delay or avoid treatment.

Neha Anand, Analyst, Biopharma Intelligence Services, Citeline, explains how the approval of Emrelis is accelerating investor interest, validating biomarker-driven ADCs, and shaping distinct strategic paths for pharma and biotech in the evolving precision oncology landscape.